Skip to content
DataLookout
Menu

NCT07014826

A Trial of HRS-5965 Capsule in Primary IgA Nephropathy

StatusActive, Not Recruiting
PhasePhase 3
Primary completion (estimated)
Track this trial

Free. We email you which fields changed when ClinicalTrials.gov updates this record.

Record History

All 3 versions: 3 with changes below. See every version on ClinicalTrials.gov ↗

  1. Notable Eligibility criteria expanded, about 26 words Show 4 more changesShow less
    • Enrollment closed, study ongoing
    • Enrollment target: estimated 378 to confirmed 389
    • Secondary endpoints: details revised at 2 of 8 entries
    • Site details revised
  2. Notable Trial status: Not Yet Recruiting to Recruiting
    • Study sites: 0 to 1
    • Start date changed from estimate of Jun 2025 to Jun 4, 2025
    v2
  3. Study First Submitted
  • Notable: the plan changed

Endpoints

Primary

Ratio of 24-hour Urinary protein to creatinine ratio (UPCR) to baseline
Timeframe: Baseline and Week 36
The total annualized slope of estimated glomerular filtration rate(eGFR)
Timeframe: Baseline and Week 104

Secondary (8)

The total annualized slope of estimated glomerular filtration rate(eGFR)
Proportion of subjects with 24-hour urinary protein excretion (24-UPE) < 0.5 g/d and < 0.3 g/d
Proportion of subjects with 24-UPCR declined >50% to baseline
Ratio of 24-hour Urinary protein to creatinine ratio (24-UPCR) to baseline
Ratio of 24-hour Urinary protein to Albumin Creatinine ratio (24-UACR) to baseline
Show 3 moreShow less
Ratio of 24-hour Urinary protein excretion(24-UPE) to baseline
Change from baseline of eGFR
Change from baseline of serum creatinine

Arms and interventions

Treatment group AExperimental

HRS-5965

Treatment group BPlacebo comparator

Placebo

Drugs: HRS-5965, Placebo

Sites

1 site in 1 country

  • Peking University First HospitalBeijing, Beijing Municipality, China